BEREC, the assembly of European national telecoms regulators, welcomed the symmetric access rules in the proposed Digital Networks Act, in particular the clarification that NRAs may intervene on their own initiative where market structures require symmetric intervention. But BEREC argued that the rules should be further strengthened and simplified, notably by replacing the list of exemptions to symmetric measures with a simpler requirement to take proportionality into account.

The US telecoms regulator, the Federal Communications Commission (FCC), voted to adopt the “Space Modernization for the 21st Century” Report and Order. This rulemaking revoked the FCC’s legacy satellite and earth station rules to create a new regime that will better align FCC rules with the nature of today’s commercial space economy. However, the rules maintain the FCC’s oversight of core regulatory concerns, such as spectrum management, harmful interference, national security, and orbital debris.

EU member states gave themselves considerable flexibility when agreeing on the information needed for the evaluation of the GIA in May 2028.

A new European Commission report concluded that one EU-wide approach to the long-term use of the 470–694 (sub-700 MHz) band is currently not feasible due to diverging national spectrum needs. Instead, member states should retain flexibility to repurpose the band beyond 2030 at different speeds, while the EU develops a common strategic approach ahead of future policy decisions and the World Radiocommunication Conference 2031 (WRC-31).

The assembly of European telecoms regulators warned against a “rushed broad-brush approach” on information requests and geographic surveys under the proposed Digital Networks Act (DNA). This may lead to less effective data gathering, while increasing costs at the same time.

The German regulator, BNetzA, notified its draft decision on Telekom Deutschland’s reference offer for access to ducts and poles. The regulator needed almost seven years from the notification that started the current round of market analysis until the decision that will define the detailed conditions of the main new remedy.